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Abstract
Introduction This is the first description of safety data for intravenous onasemnogene abeparvovec, the only approved systemically administered gene-replacement therapy for spinal muscular atrophy.
Objective We comprehensively assessed the safety of intravenous onasemnogene abeparvovec from preclinical studies,
clinical studies, and postmarketing data.
Methods Single-dose toxicity studies were performed in neonatal mice and juvenile or neonatal cynomolgus nonhuman
primates (NHPs). Data presented are from a composite of preclinical studies, seven clinical trials, and postmarketing sources
(clinical trials, n = 102 patients; postmarketing surveillance, n = 665 reported adverse event [AE] cases). In clinical trials,
safety was assessed through AE monitoring, vital-sign and cardiac assessments, laboratory evaluations, physical examinations, and concomitant medication use. AE reporting and available objective clinical data from postmarketing programs
were evaluated.
Results The main target organs of toxicity in mice were the heart and liver. Dorsal root ganglia (DRG) inflammation was
observed in NHPs. Patients exhibited no evidence of sensory neuropathy upon clinical examination. In clinical trials, 101/102
patients experienced at least one treatment-emergent AE. In total, 50 patients experienced serious AEs, including 11 considered treatment related. AEs consistent with hepatotoxicity resolved with prednisolone in clinical trials. Transient decreases
in mean platelet count were detected but were without bleeding complications. Thrombotic microangiopathy (TMA) was
observed in the postmarketing setting. No evidence of intracardiac thrombi was observed for NHPs or patients.
Conclusions Risks associated with onasemnogene abeparvovec can be anticipated, monitored, and managed. Hepatotoxicity events resolved with prednisolone. Thrombocytopenia was transient. TMA may require medical intervention. Important
potential risks include cardiac AEs and DRG toxicity.
Key Points
We comprehensively describe the overall safety data
from preclinical and clinical studies and postmarketing
data. Safety risks included hepatotoxicity, transient
thrombocytopenia, cardiac events, thrombotic microangiopathy, and ganglionopathy.
Risks associated with onasemnogene abeparvovec can be
anticipated and monitored with diligent standard of care
and sometimes require medical management.

* John W. Day
jwday@stanford.edu

1 Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive disease with an incidence of approximately 1:11,000
[1, 2]. Survival motor neuron 1 (SMN1) gene mutations
result in functional SMN protein deficiency. The most
severe forms of SMA are characterized by motor neuron
degeneration and progressive loss of muscle function
that culminates in death or permanent ventilation early in
childhood. SMA is classified into four subtypes based on
age at symptom onset and maximum motor function [3],
with approximately 45–60% of historical cases classified
as the most severe SMA type 1 [1]. Before the availability
of disease-modifying treatments, SMA was the leading
genetic cause of infant mortality [1].
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Onasemnogene abeparvovec is a gene-replacement therapy delivering a functional human SMN transgene through
nonreplicating, recombinant adeno-associated virus (AAV)
serotype 9 (AAV9). Increased SMN protein expression following treatment prevents motor neuron death, leading to
improved neuronal and muscular function.
Following intravenous onasemnogene abeparvovec, clinically meaningful efficacy outcomes have been
reported [4, 5]. Important safety risks include hepatotoxicity [6], thrombocytopenia, cardiac events, thrombotic
microangiopathy (TMA) [7], and ganglionopathy [8].
This report is the first comprehensive description of safety
data through 12 November 2020 for all clinical and preclinical experience with intravenous onasemnogene abeparvovec, the only approved systemically administered
gene therapy. Data presented here are from a composite
of preclinical studies, clinical trials, and postmarketing
sources. Postmarketing surveillance involves evaluation
of data on safety from sources such as spontaneous (voluntary) reporting, social media, published literature, market research, and public databases. While every attempt
was made to follow-up with the reporters to gain as much
information as possible, this information was not obtained
through rigorous prospective data collection. Therefore,
these data, albeit important, may not always be comprehensive. Overall, this serves as a pivotal report of the
safety profile observed thus far in this emerging class of
therapeutic options for rare monogenic disorders.

2 Methods
2.1 Preclinical Studies
Five investigative studies evaluating single-dose toxicity
and tolerability in neonatal mice and juvenile or neonatal
cynomolgus nonhuman primates (NHPs) were undertaken
using intravenous onasemnogene abeparvovec administration to mimic the drug’s intended use and to assess safety
to inform any potential safety risks that could be associated with onasemnogene abeparvovec use in humans.
Principles of the International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human
Use (ICH) M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals, ICH S6 (R1) Preclinical Safety Evaluation
of Biotechnology-Derived Pharmaceuticals, and US FDA
guidance for industry were applied. Two mouse toxicology studies were performed in accordance with good
laboratory practice guidelines at contract research organizations using a good manufacturing practices-compliant
test article representative of the pivotal clinical trial and
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commercial drug product. All other preclinical studies did
not use commercial drug product.

2.2 Clinical Trials
All seven intravenous clinical studies (Table 1) involved a
total of 102 patients as of 12 November 2020. All studies
were performed in accordance with ethical principles in
the Declaration of Helsinki and are consistent with ICH/
good clinical practice and applicable regulatory requirements. All study protocols were approved by the institutional review boards or ethics committees, with appropriate informed consent obtained. Studies were registered
with www.c linic altr i als.g ov (NCT02122952 [START],
NCT03306277 [STR1VE-US], NCT03505099 [SPR1NT],
NCT03461289 [STR1VE-EU], NCT03837184 [STR1VEAP], NCT03421977 [LT-001], and NCT04042025 [LT-002])
[4, 5, 9–12]. Eligibility requirements are described in page 3
of the electronic supplementary material (ESM).

2.3 Postmarketing Cases
Safety data (Argus Safety Database, an adverse event [AE]
management system for safety monitoring) were monitored
through voluntary reporting of AEs, literature sources, solicited venues, and social media and include 665 case reports
with 2407 AEs. Of note, literature sources were monitored
using LiSA (Literature Search Application), an assessment
and tracking tool for published safety cases and potential
safety signals. LiSA acts as a “clearing house” for collecting
scientific and medical journals and articles, and extracting,
filtering, and highlighting the relevant information. OVID
was also used to search literature databases (e.g., MEDLINE
and Embase) as part of standard safety signal detection. The
information obtained from LiSA was entered into the Argus
Safety Database. Multiple cases and/or events could be
reported for one patient. Additional details were obtained
upon follow-up from the reporting sources.

2.4 Safety Assessments
In clinical trials, safety was assessed through monitoring
AE incidence and severity, vital-sign assessments, cardiac
assessments, laboratory evaluations, physical examinations,
and concomitant medication usage. AE reporting and objective clinical data were evaluated whenever available from
postmarketing and early access programs. Data were further
analyzed to characterize AEs of special interest (AESIs),
including hepatotoxicity, thrombocytopenia, cardiac events,
TMA, and symptoms suggestive of ganglionopathy (see
page 3 in the ESM).

Open-label, singlecenter; IV; single
dose (cohort 1: single
dose 6.7 × 1013 vg/kg;
cohort 2: single dose
1.1 × 1014 vg/kg)

Open-label, single-arm,
multicenter; IV; single
dose 1.1 × 1014 vg/kg

Open-label, single-arm,
multicenter; IV; single
dose 1.1 × 1 014 vg/kg

Open-label, single-arm,
multicenter; IV; single
dose 1.1 × 1014 vg/kg

Open-label, single-arm,
multicenter; IV; single
dose 1.1 × 1014 vg/kg

Observational; NA; pts
will be followed for up
to 15 years

START; I; USA [4, 9]

STR1VE-US; III; USA
[5]

SPR1NT; III; Australia,
Belgium, Canada,
Japan, UK, USA,
Taiwan, Italy [10]

STR1VE-EU; III; Italy,
UK, Belgium, France
[11]

STR1VE-AP; III; Japan,
South Korea, Taiwan

LT-001a; long-term
follow-up; USA [12]
Up to 15 (13 actual)

≥ 6/2

Up to 30/33

1 (1 or 2)

1 (2)

SMA type (SMN2 copy
no.)

NA

NA

1, 2, 3 (1, 2, 3, 4)

1 (2)

All pts who received an
1 (1, 2)
IV infusion of onasemnogene abeparvovec

All pts who received an
1 (1, 2)
IV infusion of onasemnogene abeparvovec

All pts who received an
1, 2 (2, 3, 4)
IV infusion of onasemnogene abeparvovec

All pts who underwent
gene-therapy infusion

Any pt who underwent
gene-therapy infusion

Safety population

2.0 years as of 12 Nov.
2020

5.2 years as of 11 June
2020

18 months

18 months

18 months

18 months

24 months

Length of follow-up

Ongoing; yes

Ongoing; yes

Ongoing (enrollment
terminated for reasons
unrelated to efficacy or
safety); yes

Ongoing (enrollment
completed on 21 May
2019); yes

Ongoing (enrollment
completed on 8 Nov.
2019); yes

Completed; yes

Completed; yes

Study status; data included
in submission (yes/no)

a
Studies LT-001 and LT-002 are long-term follow-up studies. No additional gene-therapy treatment is administered to pts in these studies; however, pts are permitted to receive other
SMA therapies

IV intravenous, NA not applicable, pt(s) patient(s), SMA spinal muscular atrophy, SMN survival motor neuron gene, vg vector genome

Pts treated with onasemnogene abeparvovec
in prior efficacy/safety
studies

Pts treated with onasemnogene abeparvovec in
START

Pts with SMA type
1 with one or two
copies of SMN2 aged
< 6 months at time
of gene-replacement
therapy

Pts with SMA type
1 with one or two
copies of SMN2 aged
< 6 months at time
of gene-replacement
therapy

≥ 26/30: ≥ 14 with two
Presymptomatic pts with
copies of SMN2/14; ≥
genetically confirmed
12 with three copies of
SMA type 1 or 2 with
SMN2/15 (one pt with
two or three copies
four copies of SMN2)
of SMN2, aged ≤ 6
weeks at time of genereplacement therapy

Pts with SMA type
1 with one or two
copies of SMN2 aged
< 6 months at time
of gene-replacement
therapy

Pts with SMA type 1

15/15

Up to 20/22

Healthy participants or
diagnosis of pts

Number of pts planned/
number enrolled

Observational; NA; pts
Approximately 308/32
LT-002a; long-term
follow-up; USA,
will be followed for up
Canada, Italy, Belgium,
to 15 years from dosing
Japan, Australia
in parent study

Study design;
administration route;
treatment duration

Study; phase; country

Table 1  Overview of clinical studies with onasemnogene abeparvovec following intravenous administration
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2.5 Statistical Analyses
These aggregate data, which include a smaller data set first
described by Chand et al. [6], were analyzed using SAS version 9.4 software (SAS Institute), with all AEs coded using
conventional Medical Dictionary for Regulatory Activities
(MedDRA®) terms (version 23.1). To systematically search
for events within AESI categories, we specified predefined
standardized MedDRA® queries (SMQs). Frequency counts
were programmatically calculated for all AEs. Criteria for
deeming an AE as serious (SAE) are described in page 3
of the ESM. Vital-sign assessments, cardiac assessments,
laboratory evaluations (chemistry, hematology, urinalysis,
and immunology), and physical examinations were analyzed
to evaluate for potential clinical significance by assessing
changes over time and low, normal, and high shifts from
baseline.

3 Results
3.1 Onasemnogene Abeparvovec‑Related Toxicity
in Preclinical Safety Studies
Table 2 summarizes key preclinical findings. In mice, the
main target organs of toxicity were the heart and liver. Test
article-related mortality was observed at doses ≥ 2.4 ×
1014 vector genome (vg)/kg, with the maximum tolerated
dose at 1.5 × 1 014 vg/kg based upon atrial thrombosis starting day 17, and through day 47 postdosing, and often considered the cause of death in unscheduled sacrifice mice.
Thrombi were not observed in treated neonatal or juvenile
NHPs.
Dorsal root ganglia (DRG) mononuclear cell inflammation sometimes associated with neuronal satellitosis or
neuronal necrosis was observed 2 weeks after intrathecal
administration in cynomolgus NHPs (data not shown) [8].
Similar findings were not observed in mice.

3.2 Onasemnogene Abeparvovec‑Related Safety
Signals for Patients
Demographics and baseline clinical characteristics of
patients in the clinical studies are presented in Table 1 in
the ESM. In total, 101 of 102 patients (99%) experienced at
least one treatment-emergent AE (TEAE), and 58 patients
(56.9%) experienced TEAEs considered related to treatment
by the investigator. A total of 50 patients (49%) experienced
an SAE, of which 11 (10.8%) were considered related to
treatment (Table 3). None of the most frequently reported
SAEs (pneumonia, respiratory distress, and upper respiratory tract infection) were considered treatment related by the
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investigators. The most frequently reported treatment-related
SAEs were increased liver function test (LFT) findings and
pyrexia (two of 99 for each; 2.0%), with fewer than two
patients representing the other categories (Table 3).
In the postmarketing data set, 665 case reports containing 2407 AEs were identified, with 730 reported as SAEs.
The most common events (≥ 50 reports) were pyrexia (n =
185 reports), vomiting (n = 168), aspartate aminotransferase
(AST) increased (n = 125), alanine aminotransferase (ALT)
increased (n = 112), hepatic enzyme increased (n = 102),
platelet count decreased (n = 61), LFT results increased (n
= 57), and thrombocytopenia (n = 50).
Although sporadic changes in vital-sign values were
observed, none was persistent or deemed clinically meaningful. Blood pressure elevations were observed in association with prednisolone use. No clinically meaningful
abnormal physical examination findings in the absence
of AEs were recorded.
Deaths have been reported in children after onasemnogene abeparvovec administration (see pages 6–8 of
the ESM). Specifically, three deaths were reported in
the clinical trials as of 12 November 2020, including
two patients in STR1VE-US [5] (one who died during
the screening period and did not receive onasemnogene
abeparvovec treatment) and one patient in STR1VE-EU
[11]. Two additional deaths were reported in postmarketing data, which were assessed as not likely related to
onasemnogene abeparvovec treatment but rather more
likely because of underlying SMA.

3.3 Adverse Events of Special Interest
3.3.1 Hepatotoxicity
Data from clinical trials demonstrated elevations in aminotransferases without clinical manifestations. LFT elevations were initially observed at approximately day 7, nearly
resolved at approximately day 14, with another transient
increase at month 1, and returned to near baseline concentrations by month 2. Table 4 presents a summary of the AEs
and relevant laboratory findings.
A search of the postmarketing data set yielded 375 cases
(695 hepatic events), which were allocated to one of four categories: (1) isolated LFT elevations (337 cases, 591 events);
(2) clinical signs and symptoms (jaundice and ascites) and
events of abnormal laboratory tests, indicating coagulopathy, hypoalbuminemia, and increased ammonia (14 cases,
42 events); (3) event terms under the hepatobiliary disorders
system organ class (20 cases, 46 events); and (4) reported
diagnosis of acute liver failure (four cases, 16 events;
Table 2 in the ESM). Of note, one case may have contained
multiple event terms based on the information provided by
the reporter. Concomitant medications associated with the
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Table 2  Summary of key safety findings from nonclinical studies
Heart-related findings in mice

Onasemnogene abeparvovec-related findings in the heart consisted of inflammation, edema, fibrosis,
and features of scattered myocardial degeneration/regeneration in the ventricles of the heart
These findings were present at all doses studied, were dose-related in severity, and demonstrated
maturation from an early event predominated by inflammation, with gradual maturation of the
reaction to yield fibrosis predominantly over the 12-week timeframe of the studies with evidence of
partial reversibility
The primary findings in the atrium of the heart were thrombosis and inflammation. These findings
were dose-related and presented at doses ≥ 2.4 × 1 014 vg/kg
Atrial thrombosis was often considered the cause of death in unscheduled sacrifice mice. Whenever
present, this disorder was considered potentially life threatening and, as such, was the basis for
defining the MTD at 1.5 × 1 014 vg/kg in mice
The translatability of the observed findings in mice to primates is not known at this time
Liver-related findings in mice
Onasemnogene abeparvovec-related liver findings were noted in mice at doses ≥ 1.5 × 1 014 vg/kg
and consisted of dose-related hepatocellular hypertrophy/regeneration and, less frequently, individual cell hepatocellular necrosis and hepatocellular perinuclear vacuolization and, occasionally,
increased numbers of Kupffer cells
Findings in the liver were sometimes accompanied by modest liver enzyme increases
Liver findings were partially reversible, demonstrating progressively reduced incidence/severity over
time
DRG-related findings in NHPs
Inflammation of the DRG was noted during histopathologic evaluation of select tissues following
intrathecal administration of onasemnogene abeparvovec at 3 × 1 013 vg/animal alone and in combination with two iohexol-based contrast agents
The inflammation was characterized by minimal to marked infiltration of mononuclear inflammatory
cells, primarily lymphocytes, into the cervical, thoracic, lumbar, and sacral DRGs and associated
nerves
Minimal inflammation was associated with scattered infiltrates or small aggregates of mononuclear
cells in the DRG, without evidence of neuronal necrosis. With mild to marked inflammation,
aggregates to sheets of mononuclear cells were present, along with neuronal satellitosis, neuronal
necrosis, or neuronal loss with rare mineralization.
Inflammation was observed in ganglia from all examined levels, but incidence and severity were
generally greater in the sacral DRG
Moderate to marked inflammation was observed only in the sacral DRG in animals not administered
corticosteroids
Similar findings have been reported after administration of AAV9 vectors in monkeys and minipigs
[13, 14]
Other toxicity-related information or data Some mice affected with a form of SMA type 1 that were treated with the study vector developed
localized vascular necrosis around the ear, which is called necrotic pinna. This is believed to be
unrelated to the vector but likely related to an underlying defect that has been observed to occur in
several SMA mouse models [33]

AAV9 adeno-associated virus serotype 9, DRG dorsal root ganglia, MTD maximum tolerated dose, NHP nonhuman primate, SMA spinal muscular atrophy, vg vector genome

potential for liver injury were also reported (concomitant
acetaminophen, 18 cases; concomitant ranitidine, 19 cases).
3.3.2 Thrombocytopenia
Transient losses in mean platelet count were observed for
patients at approximately day 7 postdosing. In clinical trials, two patients had AEs of thrombocytopenia associated
with platelet values of < 75 × 109/L, neither with bleeding
concerns. One occurred in STR1VE-EU in conjunction with
multiorgan failure in the setting of sepsis and likely disseminated intravascular coagulopathy. One was an isolated AE
in STR1VE-US with a report of “platelet count decreased”
(potentially clinically significant value of 74 × 109/L) without clinical signs or symptoms. Four additional patients had

platelet-count values that met laboratory criteria for thrombocytopenia (platelet count of < 75 × 1 09/L), but they were
not reported as AEs. Nadir platelet values ranged from 4 to
74 × 1 09/L (days 2–63 postdosing, with four of six occurring ≤ 10 days postdosing). All thrombocytopenia events
that were not attributable to other causes were transient and
resolved without intervention or associated clinical sequelae.
Postmarketing surveillance data provided 134 cases
(148 thrombocytopenia events). In total, 19 unique cases
indicated a bleeding event, including four TMA cases. One
case report reflected distal lower extremity petechial rash
and thrombocytopenia (platelet count 11 × 1 09/L), which
were treated with two platelet transfusions and subsequently
resolved. All other thrombocytopenia cases in the postmarketing surveillance data were reported as bleeding events
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Table 3  Summary of related serious treatment-emergent adverse events by system organ class and preferred term for group 1 studies
System organ class; preferred term

START
STR1VE-EU STR1VE-US
1.1 × 1014
All (N = 15) 1.1 × 1014
vg/kg
vg/kg
(N = 33)
(N = 22)

SPR1NT
1.1 × 1014
vg/kg
(N = 30)

STR1VE-AP Therapeutic
IV dosea (N = 99)
1.1 × 1014
vg/kg
(N = 2)

Patients with at least one related serious
TEAE
Investigations
Alanine aminotransferase increased
Aspartate aminotransferase increased
Transaminases increased
Coagulation test abnormal
General disorders and administration site
conditions
Pyrexia
Infections and infestations
Gastroenteritis
Rhinovirus infection
Viral infection
Metabolism and nutrition disorders
Feeding disorder
Hypernatremia
Blood and lymphatic system disorders
Thrombocytopenia
Hepatobiliary disorders
Hypertransaminasemia
Nervous system disorders
Hydrocephalus

2 (13.3)

6 (18.2)

3 (13.6)

0

0

10 (10.1)

2 (13.3)
0
0
2 (13.3)
0
0

1 (3.0)
1 (3.0)
1 (3.0)
0
1 (3.0)
2 (6.1)

2 (9.1)
1 (4.5)
1 (4.5)
1 (4.5)
0
0

0
0
0
0
0
0

0
0
0
0
0
0

4 (4.0)
2 (2.0)
2 (2.0)
2 (2.0)
1 (1.0)
2 (2.0)

0
0
0
0
0
0
0
0
0
0
0
0
0
0

2 (6.1)
2 (6.1)
1 (3.0)
1 (3.0)
1 (3.0)
2 (6.1)
1 (3.0)
1 (3.0)
1 (3.0)
1 (3.0)
1 (3.0)
1 (3.0)
0
0

0
0
0
0
0
0
0
0
0
0
0
0
1 (4.5)
1 (4.5)

0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0

2 (2.0)
2 (2.0)
1 (1.0)
1 (1.0)
1 (1.0)
2 (2.0)
1 (1.0)
1 (1.0)
1 (1.0)
1 (1.0)
1 (1.0)
1 (1.0)
1 (1.0)
1 (1.0)

Data are presented n (%). Treatment-related adverse events are those that are considered possibly, probably, or definitely related to onasemnogene abeparvovec by the investigator
IV intravenous, TEAE treatment-emergent adverse event, vg vector genome

a
Therapeutic IV dose includes patients who received the therapeutic dose in START and the 1.1 × 
1014 vg/kg dose in STR1VE-EU,
STR1VE-US, SPR1NT, and STR1VE-AP

related to isolated bruising at the injection site or platelets
marginally low that were included in the broad SMQ for
hemorrhage. These thrombocytopenia cases were not associated with bleeding, hematochezia, melena, prolonged prothrombin or international normalized ratio without bleeding sign, gastrointestinal bleed approximately 1 month after
platelet normalized, or reported with a nonbleeding term.
3.3.3 Thrombotic Microangiopathy
No TMA was reported in clinical studies. Four cases were
identified in the postmarketing data set. In all reported cases,
TMA occurred within 6–11 days postdosing. Presenting features included vomiting, hypertension, oliguria/anuria, and/
or edema. Laboratory data revealed elevated serum creatinine, proteinuria and/or hematuria, and hemolytic anemia
(decreased hemoglobin with schistocytosis on peripheral

blood smear). Two patients had TMA in the setting of recent
infections. Medical interventions included one or more of
the following: blood and/or platelet transfusions; plasmapheresis; systemic corticosteroids; and eculizumab, and/or
supportive fluid, electrolyte, and hypertension management,
with one patient requiring hemodialysis. All thrombocytopenia and anemia events resolved, and serum creatinine concentrations normalized.
3.3.4 Cardiac Adverse Events
In clinical trials, 17 patients (16.7%) had at least one cardiac AE. Most were associated with transient tachycardia
or bradycardia (n = 7; 6.9%). None were reflective of intracardiac thrombi. No thrombi were reported in available
human autopsy data from two patients; however, myocardial inflammation was present in the setting of multiorgan
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Table 4  Hepatotoxicity adverse events and laboratory findings
Hepatotoxicity

START
(N = 15)

STR1VE-EU STR1VE-US SPR1NT
(N = 33)
(N = 22)
(N = 30)

Reported AEs
Elevations in LFT results (not reported as AEs)b
Postdosing elevations in LFT r esultsb
Elevations in LFT results at baseline (prior to
dosing)b

4 (26.7)
10 (66.7)
15 (100)
9 (60.0)

18 (54.5)
12 (36.4)
29 (87.9)
22 (66.7)

7 (31.8)
13 (59.1)
20 (90.9)
5 (22.7)

8 (26.7)a
19 (63.3)
26 (86.7)
20 (66.7)

STR1VE-AP
(N = 2)

Total
(N = 102)

0
1
0
0

37 (36.3)
54 (52.9)
90 (90.0)
56 (54.9)

AEs adverse events, LFT liver function test, ULN upper limit of normal
a

b

One of these events did not have laboratory abnormalities that were reported
LFTs included analysis of aspartate aminotransferase, alanine aminotransferase, and bilirubin; all were < 2 × ULN

system failure caused by sepsis. No AEs of depressed
cardiac function were reported. Baseline left ventricular ejection fraction (LVEF) was normal for all but two
patients who had borderline low values (50.8 and 55.7%).
Two additional patients each had a single post-treatment
occurrence of LVEF values that were slightly below normal but not clinically significant (51.0 and 55.4%). The
mean (±standard deviation [SD]) LVEF was 65.1% (±
5.19) at baseline and 68.9% (± 5.91) at 6 months postdosing, with similar values at 12 and 18 months.
Of the 16 patients with troponin I elevations, two had
postdosing elevations and three had baseline elevations,
which worsened in one patient without associated clinical
signs or symptoms. Two patients had elevations decrease
from baseline elevations, two of those untreated (screen
failures) had elevations, and one patient exhibited an aberrant value.
In the postmarketing data set, asymptomatic troponin I
elevations were reported; none were associated with clinical events other than a 15-month-old child with elevated
troponin I at the time of death (2 h after resuscitation).
Two postmarketing fatal cardiac arrests precipitated by
respiratory failure were reported.
3.3.5 Ganglionopathy
No AEs suggestive of ganglionopathy were reported, and a
review of documented neurologic physical examination data
in clinical studies demonstrated no findings consistent with
ganglionopathy.

4 Discussion
This report is the first comprehensive description of overall safety data from more than 800 patients treated with
onasemnogene abeparvovec and represents the first report of

overall safety associated with systemic AAV-mediated genereplacement therapy. Safety risks included hepatotoxicity,
thrombocytopenia, cardiac events, TMA, and ganglionopathy. Table 5 includes recommended mitigation strategies for
each outlined onasemnogene abeparvovec-related risk.
Hepatotoxicity observed in pivotal mouse toxicology
studies is consistent with cell-mediated immunity to the
vector capsid. Kupffer cell transduction can also elicit an
immune response [13]. Onasemnogene abeparvovec-related
liver findings in mice were sometimes accompanied by modest liver enzyme increases with attenuation over time. Similarly, liver transaminase elevations were observed with other
AAV gene therapies for humans (e.g., hemophilia B) [14].
One patient with SMA with acute liver injury presented with
AEs consistent with hepatotoxicity. Clinical laboratory values indicated liver transaminase elevations and acute liver
injury in some cases. In SMA clinical trials, these AEs were
clinically asymptomatic and resolved with prednisolone. In
two patients, liver failure was resolved with transient highdosage steroid administration [15]. All patients received
prophylactic prednisolone, but dosing and duration were
variable. Based on the current evidence, recommendations
regarding optimal prednisolone dosing should be individualized. In general, tapering of prednisolone should not commence until AST/ALT concentrations are less than two
times the upper limit of normal [6]. Of note, nearly 55% of
patients had LFT elevations at baseline, which is consistent
with those reported previously [6]. Although this suggests
that patients with SMA may have underlying hepatic abnormalities at baseline, neither the prevalence in patients with
SMA nor the relationship to SMA are known at this time.
While decreased platelet counts were reported in some
mouse studies, they were not always considered treatment
related. In clinical studies and postmarketing data, plateletcount values that met laboratory criteria for thrombocytopenia were transient and without clinical sequelae, except for
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one patient who developed late-onset thrombocytopenia (63
days postdosing) in the setting of multiorgan system failure
because of multiple concurrent infections. The mechanism
for thrombocytopenia remains unknown.
TMA represents a newly identified risk in postmarketing
surveillance. Presenting features included vomiting, hypertension, oliguria/anuria, and/or edema. Two patients had
infections before developing TMA. Thus, waiting for illness
to resolve prior to treatment with onasemnogene abeparvovec was recently recommended [16]. Encapsulated bacteria
can trigger TMA because the capsular polysaccharide is a
virulence factor, enabling immune evasion. Because any
source of immune activation can potentially trigger TMA,
it was noteworthy that both patients with preceding infections were vaccinated within 2–3 weeks of dosing. As such,
concurrent immune system activation (e.g., infection, vaccination) was identified as a potential contributing factor in
some cases. The mechanism of postdosing TMA is unknown
but might be linked to complement activation [17]. Early
recognition of TMA is critical to implementing effective

treatment. Patients may be at an elevated risk if they have
concurrent infections or other immune triggers. Further clinical investigation should be prompted when clinical signs/
symptoms emerge [7]. All four patients with TMA had elevated serum creatinine that normalized. However, creatinine
concentrations in patients with SMA must be interpreted
with care because they may be reduced secondary to diminished muscle mass.
Preclinical murine data identified the heart as a target
organ of toxicity with histopathologic evidence of inflammation and intracardiac thrombi. Onasemnogene abeparvovec-related mortality in mice was associated with atrial
thrombosis at a dose of ≥ 2.4 × 1014 vg/kg. However, no
evidence of intracardiac thrombi or echocardiogram findings
with evidence of clinical pathology was observed in primates or humans. No patterns suggestive of clinical toxicity
were identified as part of the clinical trial program, which
included troponin I, electrocardiogram, and echocardiogram
assessments. Other AAV9 vectors have been used for cardiac
transgene expression without reports of cardiac toxicity [18,

Table 5  Risk mitigation strategies
Risk

Risk mitigation strategy

Hepatotoxicity

Patients should have liver function tests conducted at baseline and on a regular basis following onasemnogene abeparvovec infusion [34]. Patients with ALT/AST/total bilirubin > 2 × ULN should not be dosed unless elevated bilirubin
is associated with neonatal jaundice
Patients should be treated with prednisolone before and after onasemnogene abeparvovec infusion [34]. Pretreatment
with oral prednisolone should be given 24 h prior to infusion with onasemnogene abeparvovec at a dosage of 1 mg/
kg/day. An equivalent dosage of another corticosteroid may be used at the discretion of the treating physician
AST/ALT/bilirubin should be assessed weekly for 30 days and every 2 weeks for an additional 60 days post administration of onasemnogene abeparvovec through the end of the corticosteroid taper, or longer if needed. Tapering of
prednisolone should not be considered until AST/ALT are < 2 × ULN [34]
Consider consultation with a pediatric gastroenterologist/hepatologist preemptively prior to dosing if necessary and/or
if elevations in aminotransferases occur [6]
If oral prednisolone is not tolerated (monitor patient for vomiting), consider IV administration of corticosteroids
Potentially hepatotoxic medications should be avoided when possible [6]
Thrombocytopenia
Platelet counts should be obtained before onasemnogene abeparvovec infusion and monitored on a regular basis afterwards: weekly for the first month and every other week for the second and third months until platelet counts return to
baseline [34]
TMA
Early recognition of TMA is imperative, as TMA may require such therapeutic interventions as plasmapheresis, dialysis, or pharmacotherapy to lessen associated morbidity and mortality [7]
TMA is a clinical diagnosis: signs and symptoms may include vomiting, pallor, petechiae, purpura, oliguria, pitting
edema, hypertension, and seizures. While routine platelet-count monitoring is recommended at baseline and regular
intervals postdosing [34], clinical suspicion and increased awareness should guide the clinician in the event that
additional evaluation is warranted
If thrombocytopenia is present and there is a clinical suspicion of TMA, further evaluation, including hemoglobin and
testing for hemolysis and renal dysfunction (including urinalysis), also should be obtained [7]
Consult a pediatric nephrologist/pediatric hematologist/pediatric intensivist immediately in suspected cases for further
evaluation and management
Cardiac events
Troponin I should be obtained at baseline and monitored for at least 3 months following onasemnogene abeparvovec
infusion or until concentrations return to within normal reference range for patients with SMA [34]
Should elevations in troponin occur, the patient should be evaluated for signs or symptoms of cardiac dysfunction, with
a pediatric cardiologist consulted, if necessary
DRG cell inflammation A detailed neurologic examination should be conducted. If abnormalities are detected, further evaluation should be
undertaken as clinically warranted
ALT alanine aminotransferase, AST aspartate aminotransferase, DRG dorsal root ganglion, IV intravenous, SMA spinal muscular atrophy, TMA
thrombotic microangiopathy, ULN upper limit of normal
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19]. In addition, the significance of troponin elevations in
children remains unclear [20].
Patients had no overt clinical symptoms/signs of sensory
neuropathy suggesting DRG inflammation as reported by the
investigators. The preclinical onasemnogene abeparvovecrelated DRG findings were comparable with those observed
with several other intrathecal- or intravenous-administered
AAV gene therapies using similar or assorted capsids and
transgenes in NHPs and appear to be an AAV class effect
[21, 22]. The DRG microscopic findings were generally
asymptomatic, with onset within weeks of dose administration. These findings do not indicate progressive courses,
but they do display morphologic features of expected tissue
remodeling [22]. The mechanism and translational relevance
for humans is uncertain. Identification of ganglionopathies
in children is often challenging. Several histologic studies
for humans demonstrated degeneration in sensory neurons,
DRG, and motor neurons in various diseases, including SMA
type 1 [23]. The utility of electrophysiology in children with
SMA appears variable. Small studies have reported normal
sensory examinations and electrophysiology in patients with
SMA type 2 or 3 [24]. Another analysis of 106 patients with
SMA demonstrated that 32.0% (16/50) of those with SMA
type 1, 15.8% (6/38) of those with SMA type 2, and 22.2%
(4/18) of those with SMA type 3 had absent sensory nerve
action potentials [25]. Interpreting sensory nerve action
potential data for SMA related to the diagnosis of an inflammatory ganglionopathy was not straightforward as electrophysiologic findings are highly influenced by extremity temperature, electrode size, and electrode pressure [26] and are
prone to errors in distance measurement, stimulation, and
recording. These challenges limited the ability to delineate
the true prevalence of sensory nerve abnormalities in SMA.
Deaths have been reported for children after onasemnogene abeparvovec administration (see pages 6–8 in the
ESM). The natural history of absolute survival probabilities for children with SMA type 1 at ages 1, 2, 4, and 10
years was 40%, 25%, 6%, and 0%, respectively [27]. The
mortality rate postdosing was two of 102 (1.9%) patients
in the clinical trials and two of 600 (0.3%) events outside of clinical trials; deaths were considered unrelated to
treatment by the investigator and sponsor. Although survival of children with SMA type 1 has improved during
the past 3 decades because of improved respiratory and
nutritional management, per the standard-of-care guidelines [28, 29], the mean age of death (±SD) was 10.4–48
months (3.4–4.0) [30], with some patients surviving for
up to 24 years [31]. With more aggressive ventilatory and
nutritional support, median survival time was 24.0 months
for those born between 1995 and 2006 [30]. Furthermore,
survival probability at age 12 months was 79.3% (n = 78).
Thus, recognizing the potential comorbidities that these
medically complex children face and ensuring that each

patient is in the optimal state of health before and at the
time of dosing (i.e., no signs/symptoms of infection) is
critical.
Long-term follow-up analysis of patients in the START
study (median time since dosing of 5.2 years [range
4.6–6.2] as of 11 June 2020) has not identified new safety
signals [12]. However, as recommended in a recent European ad hoc consensus statement [32], further studies analyzing the long-term effects of gene therapy for SMA are
necessary.
The present study is limited by the inherent nature of
reporting postmarketing data because reporting is spontaneous (voluntary) and also includes sources such as social
media, published literature, market research, and public
databases. Therefore, these data may not be complete or
capture details such as alternate etiologies, potential confounders, and time to resolution of AEs, if applicable.

5 Conclusion
This comprehensive integrated assessment of safety information indicates that, although the risks of onasemnogene
abeparvovec administration might be serious if not anticipated and recognized early, they can be managed through
diligent standard of care, sometimes requiring medical
intervention.
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